459 related articles for article (PubMed ID: 20203154)
1. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Bjerre Knudsen L; Madsen LW; Andersen S; Almholt K; de Boer AS; Drucker DJ; Gotfredsen C; Egerod FL; Hegelund AC; Jacobsen H; Jacobsen SD; Moses AC; Mølck AM; Nielsen HS; Nowak J; Solberg H; Thi TD; Zdravkovic M; Moerch U
Endocrinology; 2010 Apr; 151(4):1473-86. PubMed ID: 20203154
[TBL] [Abstract][Full Text] [Related]
2. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.
Rosol TJ
Toxicol Pathol; 2013 Feb; 41(2):303-9. PubMed ID: 23471186
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
Hegedüs L; Moses AC; Zdravkovic M; Le Thi T; Daniels GH
J Clin Endocrinol Metab; 2011 Mar; 96(3):853-60. PubMed ID: 21209033
[TBL] [Abstract][Full Text] [Related]
4. Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.
Boess F; Bertinetti-Lapatki C; Zoffmann S; George C; Pfister T; Roth A; Lee SM; Thasler WE; Singer T; Suter L
J Mol Endocrinol; 2013 Jun; 50(3):325-36. PubMed ID: 23463748
[TBL] [Abstract][Full Text] [Related]
5. Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.
Vahle JL; Byrd RA; Blackbourne JL; Martin JA; Sorden SD; Ryan T; Pienkowski T; Wijsman JA; Smith HW; Rosol TJ
Endocrinology; 2015 Jul; 156(7):2409-16. PubMed ID: 25860028
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.
Madsen LW; Knauf JA; Gotfredsen C; Pilling A; Sjögren I; Andersen S; Andersen L; de Boer AS; Manova K; Barlas A; Vundavalli S; Nyborg NC; Knudsen LB; Moelck AM; Fagin JA
Endocrinology; 2012 Mar; 153(3):1538-47. PubMed ID: 22234463
[TBL] [Abstract][Full Text] [Related]
7. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
9. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Gaspari T; Liu H; Welungoda I; Hu Y; Widdop RE; Knudsen LB; Simpson RW; Dear AE
Diab Vasc Dis Res; 2011 Apr; 8(2):117-24. PubMed ID: 21562063
[TBL] [Abstract][Full Text] [Related]
10. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
Chiu WY; Shih SR; Tseng CH
Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring glucagon-like peptide-2 (GLP-2) receptors in human intestinal cell lines.
Sams A; Hastrup S; Andersen M; Thim L
Eur J Pharmacol; 2006 Feb; 532(1-2):18-23. PubMed ID: 16448646
[TBL] [Abstract][Full Text] [Related]
12. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
13. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
Dubé PE; Forse CL; Bahrami J; Brubaker PL
Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
15. Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor alpha4 impairs thyroid calcitonin production in young mice.
Lindfors PH; Lindahl M; Rossi J; Saarma M; Airaksinen MS
Endocrinology; 2006 May; 147(5):2237-44. PubMed ID: 16497798
[TBL] [Abstract][Full Text] [Related]
16. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.
Waser B; Beetschen K; Pellegata NS; Reubi JC
Neuroendocrinology; 2011; 94(4):291-301. PubMed ID: 21893952
[TBL] [Abstract][Full Text] [Related]
17. Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.
Bulchandani D; Nachnani JS; Herndon B; Molteni A; Pathan MH; Quinn T; Hamdan HA; Alba LM; Graves L
Eur J Pharmacol; 2012 Sep; 691(1-3):292-6. PubMed ID: 22819704
[TBL] [Abstract][Full Text] [Related]
18. Regulation of glucagon and glucagon-like peptide-1 receptor messenger ribonucleic acid expression in cultured rat pancreatic islets by glucose, cyclic adenosine 3',5'-monophosphate, and glucocorticoids.
Abrahamsen N; Nishimura E
Endocrinology; 1995 Apr; 136(4):1572-8. PubMed ID: 7534705
[TBL] [Abstract][Full Text] [Related]
19. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line.
Crespel A; De Boisvilliers F; Gros L; Kervran A
Endocrinology; 1996 Sep; 137(9):3674-80. PubMed ID: 8756532
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats.
Romaní-Pérez M; Outeiriño-Iglesias V; Gil-Lozano M; González-Matías LC; Mallo F; Vigo E
Endocrinology; 2013 Mar; 154(3):1144-55. PubMed ID: 23354098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
